Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Non-cash Items (2019 - 2025)

Eton Pharmaceuticals' Non-cash Items history spans 7 years, with the latest figure at $5.8 million for Q3 2025.

  • For Q3 2025, Non-cash Items fell 48.26% year-over-year to $5.8 million; the TTM value through Sep 2025 reached $5.8 million, down 48.26%, while the annual FY2024 figure was $4.0 million, 18.95% up from the prior year.
  • Non-cash Items for Q3 2025 was $5.8 million at Eton Pharmaceuticals, down from $8.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $46.6 million in Q1 2025 and bottomed at $437000.0 in Q3 2022.
  • The 5-year median for Non-cash Items is $4.0 million (2024), against an average of $6.7 million.
  • The largest annual shift saw Non-cash Items plummeted 76.48% in 2021 before it skyrocketed 618.48% in 2023.
  • A 5-year view of Non-cash Items shows it stood at $2.7 million in 2021, then crashed by 83.88% to $437000.0 in 2022, then soared by 678.01% to $3.4 million in 2023, then grew by 18.95% to $4.0 million in 2024, then surged by 43.22% to $5.8 million in 2025.
  • Per Business Quant, the three most recent readings for ETON's Non-cash Items are $5.8 million (Q3 2025), $8.5 million (Q2 2025), and $46.6 million (Q1 2025).